{"id":885137,"date":"2025-09-10T09:26:23","date_gmt":"2025-09-10T13:26:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/"},"modified":"2025-09-10T09:26:23","modified_gmt":"2025-09-10T13:26:23","slug":"nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/","title":{"rendered":"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl"},"content":{"rendered":"<div class=\"mw_release\">\n<p>ORLANDO, Fla., Sept.  10, 2025  (GLOBE NEWSWIRE) &#8212; Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA\u2122 Fentanyl which has been granted a Type C meeting on September 18<sup>th<\/sup>.<\/p>\n<p>Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company produced a record six months, reporting revenue of $1,289,884, up 50.87% YOY.<\/p>\n<p>Progress continues on the development of AVERSA Fentanyl, Nutriband is reminding exiting shareholders and updating new shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse Potential study. Importantly, no Phase 2 or Phase 3 clinical trials will be required before submission.<\/p>\n<p>If approved, AVERSA Fentanyl could become the first and only abuse-deterrent transdermal patch available globally. AVERSA Fentanyl is estimated to have the potential to reach peak annual sales of $80-$200 million, according to a market analysis report from Health Advances.<\/p>\n<p>AVERSA Buprenorphine, which is the company\u2019s second application for AVERSA, is projected to reach peak annual sales of up to $130 million.<\/p>\n<p>As of July 31, 2025, Nutriband\u2019s cash reserves stand at $6.9 million, supporting the company\u2019s ongoing development and commercialization efforts for AVERSA Fentanyl. The company\u2019s total assets are valued at $10.17 million, with stockholders\u2019 equity amounting to $8.5 million.<\/p>\n<p>\n        <strong>About Nutriband Inc.<\/strong>\n      <\/p>\n<p>We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA\u2122 abuse-deterrent technology. AVERSA\u2122 technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.<\/p>\n<p>The Company\u2019s website is <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MiGYBbolxVRr8wpRVxbFjxSu0Ps6LZls8U7Xy_kizOmtPvEVjUYUdJcGA4GBt-WNArKjvR3eX7XoG2Gww92mKfcGIpRqZR7-fUZar5xDqNk=\" rel=\"nofollow\" target=\"_blank\">www.nutriband.com<\/a>. Any material contained in or derived from Company\u2019s websites or any other website if not part of this press release.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Certain statements contained in this press release, including, without limitation, statements containing the words \u2018\u2019believes,\u201d \u201canticipates,\u201d \u201cexpects\u201d and words of similar import, constitute \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company\u2019s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company\u2019s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company\u2019s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d in the Company\u2019s Form S-1, Form 10-K for the year ended January, 2025, filed April 28, 2025, the Forms 10-Q\u2019s filed subsequent to the Form 10-K in 2025, and the Company\u2019s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.<\/p>\n<p>For more information, contact:<\/p>\n<p>Nutriband Inc. <br \/>Phone: 407-377-6695<br \/>Email: info@nutriband.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzgyNGJlMzAtMzNlZS00NGM4LThmZTMtNTA2YzExY2E1OWU4LTEzMDgzNDktMjAyNS0wOS0xMC1lbg==\/tiny\/Nutriband-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) &#8212; Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA\u2122 Fentanyl which has been granted a Type C meeting on September 18th. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company produced a record six months, reporting revenue of $1,289,884, up 50.87% YOY. Progress continues on the development of AVERSA Fentanyl, Nutriband is reminding exiting shareholders and updating new shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-885137","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) &#8212; Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA\u2122 Fentanyl which has been granted a Type C meeting on September 18th. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company produced a record six months, reporting revenue of $1,289,884, up 50.87% YOY. Progress continues on the development of AVERSA Fentanyl, Nutriband is reminding exiting shareholders and updating new shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a &hellip; Continue reading &quot;Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-10T13:26:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl\",\"datePublished\":\"2025-09-10T13:26:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/\"},\"wordCount\":658,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/\",\"name\":\"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=\",\"datePublished\":\"2025-09-10T13:26:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/","og_locale":"en_US","og_type":"article","og_title":"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - Market Newsdesk","og_description":"ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) &#8212; Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA\u2122 Fentanyl which has been granted a Type C meeting on September 18th. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company produced a record six months, reporting revenue of $1,289,884, up 50.87% YOY. Progress continues on the development of AVERSA Fentanyl, Nutriband is reminding exiting shareholders and updating new shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a &hellip; Continue reading \"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-10T13:26:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl","datePublished":"2025-09-10T13:26:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/"},"wordCount":658,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/","name":"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=","datePublished":"2025-09-10T13:26:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjQyOCM3MTM5MjgzIzIyOTY3OTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nutriband-inc-quarterly-report-highlights-record-revenue-for-q2-2025-up-50-87-yoy-and-strategic-progress-toward-nda-filing-for-aversa-fentanyl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/885137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=885137"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/885137\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=885137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=885137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=885137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}